View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 21, 2022

SeaStar Medical seeks FDA HDE approval for Selective Cytopheretic Device

SCD removes the cytokine storm that causes organ failure, inflammation, and possible death in critically ill patients.

SeaStar Medical has submitted an application seeking a humanitarian device exemption (HDE) approval from the US Food and Drug Administration (FDA) to use its Selective Cytopheretic Device (SCD) for the treatment of children with acute kidney injury (AKI).

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

An extracorporeal device, SCD has been designed to be used with continuous renal replacement therapy (CRRT) to selectively target hyperactive neutrophils and monocytes.

Using immunomodulating technology, the device removes the cytokine storm that causes organ failure, inflammation and possible death in critically ill patients.

The new SCD technology sequesters and neutralises activated toxic neutrophils and provides a new treatment approach for systemic inflammatory response syndrome.

The company stated that the FDA has accepted the HDE application and will start reviewing it.

SeaStar Medical CEO Eric Schlorff said: “The FDA’s acceptance of the HDE application represents an important step forward in helping paediatric specialists care for these critically-ill children.

“We believe use of the SCD holds tremendous promise for these patients and look forward to working closely with the FDA in the review of our application.”

The submission of the HDE application is based on data obtained from the company’s open-label, multi-centre pilot clinical study of SCD in paediatric patients with AKI.

The study was designed to evaluate SCD’s safety and feasibility in paediatric patients with AKI and multi-organ dysfunction (MOD) that required CRRT.

The device was found to be safe for use in paediatric patients.

The study met its endpoints of safety as well as reduced mortality and dialysis dependence in patients treated with SCD at day 60.

Last month, SeaStar Medical and LMF Acquisition Opportunities reported data from the SCD 005 clinical study of SCD in Covid-19 patients with multiple organ failure admitted to the intensive care unit (ICU).

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network